The versions affected are called compounded medications, which have the same active ingredients as the name brands. The ...

Copycat versions of Eli Lilly's diabetes drug Mounjaro and obesity drug Zepbound were supposed to go away this week. They're ...

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

Discover why Eli Lilly and Company is set for a strong 2024 with a robust pipeline, solid financials, and strategic growth ...

The makers of weight-loss drugs Wegovy and Zepbound are lowering prices significantly, effective immediately, to make them more affordable.

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

Eli Lilly (LLY 1.80%) has been around for almost 150 years, finding ways to innovate and grow. Today, it's the most valuable ...

Investors with a lot of money to spend have taken a bearish stance on Eli Lilly LLY. And retail traders should know. We ...

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety ... Lilly makes tirzepatide, commercialized ...

Eli Lilly and Company (NYSE:LLY) also made substantial progress across its strategic deliverables in fiscal Q4 2024, with ...

Novo Nordisk has lowered Wegovy's monthly cost by 23%, and Eli Lilly cut prices for Zepbound's starter dose to $349 per month. HealthDay News — The makers of two popular weight-loss drugs — Wegovy and ...